Camel-IDS

Developing radio-immunotherapeutic drugs for cancer patients.

Total raised

€37M

€37,000,000

Funding rounds

Investors

distinct backers

Active since

2018-11

latest 2018-11

Funding by year

EUR raised per year

High confidence

Raise-next likelihood16

base rate 44% for Series A

Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.

1 rounds

Date	Stage	Amount	Investors
2018-11-21	Series A	€37M	Gimv,V-Bio Ventures	View deal →

same sector or country